Stock Market Impact: Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares rose 3.2% in after‑hours trading on Wednesday following the Therapeutic Goods Administration (TGA) of Australia granting conditional approval for its melanoma therapy Amtagvi (lifileucel).
Regulatory Details: The TGA approval is the third marketing authorization for Amtagvi and represents the first T‑cell therapy approved for a solid‑tumor cancer in Australia. The therapy is indicated for adult patients with unresectable or metastatic melanoma previously treated with a PD‑1 blocking antibody, and if BRAF V600 mutation‑positive, a BRAF inhibitor with or without a MEK inhibitor.
Clinical Evidence: Approval was based on safety and efficacy data from the global, multicenter C‑144‑01 Phase 2 trial, which enrolled patients with metastatic melanoma previously treated with at least one systemic therapy (including PD‑1 blockade and, where applicable, BRAF ± MEK inhibitors). Efficacy was demonstrated via objective response rate and duration of response assessed by an Independent Review Committee per RECIST v1.1.
Market Expansion: Iovance announced it is authorising its first Australian treatment centre as part of an expansion strategy targeting markets with high advanced melanoma prevalence.
Epidemiology Context: Australia has the world’s highest melanoma incidence, with an estimated 17,000 new cases and more than 1,500 deaths annually, making the approval a significant addition to treatment options after anti‑PD‑1 and targeted therapies.
